Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Inflammation, Erythropoiesis, and Iron Metabolism in T2DM with CKD
NCT06820567Phase 3Not yet recruiting
- Sponsor
- Assiut University
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by Assiut University. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06820567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06820567.